<DOC>
	<DOCNO>NCT02127372</DOCNO>
	<brief_summary>This Phase 1/Phase 2 study STI571 combine docetaxel cisplatin treatment patient recurrent metastatic Non-Small Cell Lung Cancer ( NSCLC ) . This research study 2 part . The first part ( Phase 1 ) call dose-escalation . Not subject enrolled phase study receive dose . The purpose dose-escalation determine high safe dose STI571 use combination docetaxel cisplatin . That dose use Phase 2 .</brief_summary>
	<brief_title>Maximum Tolerated Dose , Safety Efficacy Docetaxel / Cisplatin + STI571</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients must histologically cytologically recurrent , advanced NSCLC : Stage IV disease ; Stage IIIB due malignant pleural effusion allow successfully pleurodesed . Tumor tissue slide must express phosophorylated pdgfrB IHC . At least one measurable target lesion define RECIST criterion irradiate . No prior chemotherapy treatment disease allow . Patients brain metastasis , appropriate treatment , neurologically stable least 12 week ( steroid ) prior study enrollment . ECOG performance status 01 . Meets initial laboratory parameter . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Exclusion Criteria Any prior treatment biologic response modifier chemotherapeutic agent disease . Any concomitant malignancy except nonmelanoma skin cancer insitu carcinoma cervix . History allergic reaction attribute compound similar chemical biologic composition STI571 and/or docetaxel , drug formulate polysorbate 80 and/or cisplatin . Patients : Contrast allergy . GI bleed ≤ 1 month study enrollment . Intermittent chronic oxygen requirement . Pulse oximetry &lt; 90 % . Grade 3 dyspnea . History poorly regulate anticoagulation warfarin . Edema fluid retention grade &gt; 1 . Neuropathy grade ≥1 . Uncontrolled intercurrent medical illness include , limited , ongoing active infection require IV antibiotic , symptomatic congestive heart failure , unstable angina pectoris , ≤3 month myocardial infarction cardiac arrhythmia . Psychiatric illness/social situation would limit compliance study requirement would prevent informed consent psychiatric illness/social situation require inpatient treatment within past 3 month . Any type hearing impairment . Known HIV infection . Receiving investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>non-small cell</keyword>
	<keyword>lung cancer</keyword>
</DOC>